Monday, November 09, 2009
CancerView.ca - search results - NIL
Canadian Partnership Against Cancer and affiliate:
Search Results:
SAGE
Target Population -
Age: Adult
Continuum Of Care: Treatment
Type of Cancer: Gynecology
No results found to display
Body mass index as a prognostic factor in epithelial ovarian cancer and correlation with clinico-pathological factors
Conclusion. Overweight and obese patients did not have worse survival than normal weight and underweight patients. The prognostic impact of BMI on survival was only noted for underweight patients with serous tumors.
QUOTE chemo: A patient-centred instrument to measure quality of communication preceding chemotherapy treatment through the patient’s eyes
QUOTE: Odd how the p in patients' is in small caps ??
Sunday, November 08, 2009
Saturday, November 07, 2009
Friday, November 06, 2009
Treatment decision making and its discontents
Soc Work Health Care. 2009 Aug-Sep;48(6):614-34.
Treatment decision making and its discontents.
Sinding C, Wiernikowski J.
Department of Health, Aging, and Society, and School of Social Work, McMaster University, Hamilton, Ontario, Canada. sinding@mcmaster.ca
Patient participation in treatment decision making is held as a virtue in clinical contexts, and has much to recommend it. Yet important questions have been raised about the assumptions underlying models of patient participation. Debates have arisen about the significance of medically defined risks and outcomes of treatment; the adequacy and relevance across social groups of the concept of autonomy; and the emphasis on the professional-patient dyad. This article contributes to the debate about treatment decision making with reference to a study focused on older women with cancer. Interviews with patients and cancer care professionals highlighted the salience to patients' treatment choices of experiential knowledge, social roles and responsibilities, and the health policy context. It appears that prevailing models of decision making may obscure patients' more typical decision processes as well as the social determinants of those choices.
The Contents and Readability of Informed Consent Forms for Oncology Clinical Trials
CONCLUSIONS:: ICF had acceptable readability and provided a realistic overview of the benefits and risks of clinical trials, but the potential for hospitalization or fatality was underreported.
Thursday, November 05, 2009
Update: H1N1 and Cancer
A miracle. Our ovarian cancer friend is now in the hospital and receiving the care that she feels she needs and which she deserves. A good news story!
Wednesday, November 04, 2009
Update - from Nov 3rd - Letter to the Editor H1N1 and Cancer (ovarian cancer woman in need)
Editor's Comment: I received this response and have forwarded the information on to my ovarian cancer friend. It was sent onwards (obviously). One small step and although only the friend herself will know if this will be helpful, it is one small step.
Sandi
Dear Ms. Pnaiuskas, can you forward to her the information that I sent you yesterday? She can also contact me directly.
Thanks,
BC Cancer Agency WebQueries
604-675-8005 604-675-8009
1-888-675-8000, local 8005
* 675 West 10th AvenueVancouver, BC V5Z 1L3
Tuesday, November 03, 2009
Sunday, November 01, 2009
H1N1 and Cancer - update
Letter to the Editor;
With the focus of attention on H1N1 are we allowing care for those desparately ill to go to the bottom of today's priority list? It would seem so. I have a friend in need. The cancer is killing both of us. The cancer is killing my friend because of the disease. It is killing me because I am sitting here watching and listening to this friend who needs help but cannot access palliative care assistance. It seems that this patient has tried to access help without success. I believe there must be a healthcare provider somewhere in this province, who can exercise some form of a miracle and connect the dots. Out of privacy concerns I will not publicly provide this patient's personal information but what I do need is someone in the Vancouver area who has the authority, ability and willingness to help this patient. As a cancer survivour and friend, the best I can do is place a call for action. As a healthcare provider, you have the means to make it work. I will connect you. Please help because we need to and we must. Sandi Pniauskas October 30, 2009 http://ovariancancerandus.blogspot.com http://ovariancancerdebate.blogspot.com/ November 1st, 2009 update: This letter was circulated through
media outlets, Twitter, Facebook, listservs, professional organizations etc. With the exception
of Charles Adler (media broadcaster) and 2 cancer survivours it fell on deaf ears.
Initial evaluation and referral guidelines for management of pelvic/ovarian masses - Canada
"Patients deemed to have a high risk of an underlying malignancy should be reviewed in consultation with a gynaecologic oncologist for assessment and optimal surgical management."
Who are the providers of gynaecologic cancer surgical care in Ontario?
Laparoscopic peritoneal entry preferences among Canadian gynaecologists
Abstract: the response rate to the survey was 45.6%
"CONCLUSIONS: Our survey had a significant response rate and was able to delineate current laparoscopic entry practice patterns of gynaecologists, which were consistent across Canada. Despite 72.9% of respondents reporting familiarity with the recent SOGC clinical practice guideline, it appears that clinical practice does not necessarily coincide with current recommendations. These variances in gynaecological practice emphasize the need for further educational initiatives to ensure that the evidence from research is used to make clinical practice safer."
Saturday, October 31, 2009
patient advocacy
Today, as I ponder spending the past 48 hrs trying to help this friend, I am disgusted with the lack of response. How can this be? (see letter below)
H1N1 and Cancer
Letter to the Editor;
With the focus of attention on H1N1 are we allowing care for those desparately ill to go to the bottom of today's priority list? It would seem so.
I have a friend in need. The cancer is killing both of us. The cancer is killing my friend because of the disease. It is killing me because I am sitting here watching and listening to this friend who needs help but cannot access palliative care assistance. It seems that this patient has tried to access help without success. I believe there must be a healthcare provider somewhere in this province, who can exercise some form of a miracle and connect the dots. Out of privacy concerns I will not publicly provide this patient's personal information but what I do need is someone in the Vancouver area who has the authority, ability and willingness to help this patient. As a cancer survivour and friend, the best I can do is place a call for action.
As a healthcare provider, you have the means to make it work. I will connect you. Please help because - we can and we must.
Sandi Pniauskas
sandipn@sympatico.ca
October 30, 2009
Hope with More: In Their Own (Ovarian Cancer) Words
reposted from September 11th:
Hope with More: ‘In Their Own (Ovarian Cancer) Words’©
September 11th, 2009
Author: Sandi Pniauskas
Still today, less than 20% of ovarian cancers are diagnosed in early stages, primarily one of luck or happenstance. Ever-present are the realities that ovarian cancer is a disease most often en-shrined in significant suffering. This is our past and this is our current reality.
Reflecting on our women’s most intimate and unpublished thoughts, feelings and opinions tells, ‘In Their Own (Ovarian Cancer) Words’, what still has not and is not being heard. This is not the ‘cute’ side of ovarian cancer, although there are moments. Each day brings a kaleidoscope of emotions. With each passing day, the struggles of the fine line between Hope, Reality, Wishes, Expectations and Dreams remain.
We speak as one without boundaries and indeed in many respects ovarian cancer IS the silent killer. Against our will and with significant sacrifices, this ovarian cancer invariably defeats the body and the spirit. I challenge you to listen, as we have, so silently, for so long. A decade of intimate involvement with ovarian cancer women, their caregivers and communities, has most often elicited truisms that stand out. There is Trust between Survivors & Caregivers and secondly, there does not exist, in our world, an ‘ordinary’ ovarian cancer woman.
Trust between ovarian cancer Women and Caregivers is: Hope with More.
Should we choose we might learn much based on these personal conversations. These few words represent a microscopic-sampling of millions of words and thoughts - all valued - all cherished – sometimes dismissed. Sometimes too difficult to b/hear. Sometimes with a huge sigh of relief and humour.
In our communities, many moments are spent living-with-ovarian cancer, often through the eyes of others. As a tribute to our ovarian cancer women, living-with or in-spirit, these are their words to you with that special privilege of Trust and my own personal admiration… in their own words. Some are stunning. All are real.
Age:
A: Ovarian cancer for xx-something ‘dummies’.
L: Older than whom?
I: How dare they write me off.
S: I have wished it was me, not her going thru this . Though I am younger and could be stronger, the truth is I am such a coward compared to her.
Angels & Hope & Friends:
B: I am alive today because of my guardian angel {an ovarian cancer survivor).
B: Spent all day in emergency because I was having a lot of trouble breathing. Good news no heart
attack, no stroke.
R: Please visit me today as I think this is it…. Please visit me today as I think this is it….(X many) … Look after yourself and when you have time, contact me at: 1 – 800 – HEAVEN ext R … Message to R: The line has been kind of busy ....
Y: Friendship therapy is something that has not been explored by the medical community, but it is important for cancer survivors. When I was on chemotherapy, I might just sleep over some days because during those days I was too sick to eat or get up. I was surprised I was enjoying not only the good companies, but also the food when other survivors came to visit me.
L: …will be shutting down the computer now...we’ll see each other completely on the other side.
C: I agree, let’s go, we can. (do this)
C: I think I will lean heavily on philosophy as I get closer to dying. It's that or religion. There's always food! Maybe I'll just eat my way through the fear of death!
S: I have to say that I am not being very gracious here and at the same time not feeling that I should
apologize either. It makes me feel that I am supposed to be wishing you the best when all I really am
wishing for is that you could stay.
CA125:
S: I was 3x years old when I was diagnosed…. I have never had a CA 125 done to my knowledge.
S: It doesn’t matter what the research on the CA125 says - it’s all we have.
Humor:
J: (Dr.) said if his wife was going for (treatment) this is who he would send her to. I hope he likes his wife!!!!
S: I should have read the bio first - psychiatry and 'suck it up' don't really go together.
S: Thanks for living so long! (woman with 150~ + chemo/multiple surgeries TO woman with no recurrence)
L: This disease may have taken my ovaries but has replaced them with a ‘set of balls’.
Husbands/Partners:
D: I watched, as the verdict was read, a tsunami-like wave pass right over my wife’s head, leaving her completely stunned.
Knowledge:
A: Ovarian cancer for xx-something ‘dummies’. (worth repeating)
S: In order to be taken seriously, we (patients) need to understand everything about ovarian cancer.
C: I decided that starvation is the easier death by far….
B: I once read that ovarian is the most complicated cancer, so I figure that I (and the rest of us) must be really special.
Impact:
B: “You need a surgeon and you need one now”. I left his office naively thinking that something would be done and that we could go back to trying to have children.
L: (upon my death) please thank everyone in our group...they are so special.
R: (favourite quote) "Since my house burned down I now have a better view of the rising moon."
F: I always wonder which (ovarian cancer friend’s) death will put me over the edge. I think I am close.
Value and Sense of Worthiness:
K: I feel I am nothing for what this disease is doing to my family (control)….I am not a nothing...I am really a somebody...somebody with ovarian cancer.
L: Let me tell you what is on my mind without cutting me off with "You are so negative!” It is not that I am being negative, these are the facts and I am being realistic.
D: (word games) I Am No Thing. I Am. Not a Thing, or a title, nor am I a summary of accomplishments. I am No Thing because I am not static, not uniform, not in a box, not a disease, not a political party. I am not a snapshot.
C: (published) “Devaluing a Survivor’s Challenge”
We are: PhD’s, healthcare support professionals, lawyers, bankers, physicians, teachers, social workers, computer specialists, nurses, realtors, bankers, e-patients...…Daughters, Sisters, Mothers, Grandmothers
*As matters of integrity, names have not been disclosed, albeit many have given their express permission to do so (past and present)
Friday, October 30, 2009
$5.4 million Quebec breast cancer wait list class action settlement approved by court Patients who experienced post-surgery radiotherapy treatment...
$5.4 million Quebec breast cancer wait list class action settlement approved by court
Patients who experienced post-surgery radiotherapy treatment delays must file claims by March 31, 2010
2007 British Columbia PET scans approved for gyn cancers
vs zero for Ontario
reference document for B.C. criteria
Correspondence: Molecular Screening for Lynch Syndrome: From Bench to Bedside
Lynch syndrome is the most prevalent familial cancer. Screening
can prevent death from new colon and endometrial cancers among
the patients and family members. We urge the implementation of a
molecular screening for all colorectal cancer patients and suggest
taking advantage of BRAF and methylation analyses in MLH1-
negative cases to select the patients at highest risk.
To find a global solution to cancer, we need a global conversation - The Globe and Mail
To find a global solution to cancer, we need a global conversation - The Globe and Mail:
"The patient rarely, if ever, has a meaningful role in their care or any real power in the health system.
The public and patients rarely have a voice."
Thursday, October 29, 2009
Ontario Ministry of Health Rejecting OSCAR is a $1 Billion Mistake.
"The province has rejected McMaster University's offer to get every family doctor using electronic health records within two years.
McMaster said it would need less than $20 million to get the 8,000 family doctors still using paper files in Ontario switched to an electronic health records system created by the university and called OSCAR.
But the Ministry of Health says it's sticking to its policy of letting individual doctors decide whether they want electronic health records and what system to use.
Theoretical model of treatment strategies for clear cell carcinoma of the ovary: Focus on perspectives
" ..the therapy currently used in renal CCC should be considered as an alternative for the present treatments or an attractive therapeutic option for ovarian CCC."
Wednesday, October 28, 2009
Tuesday, October 27, 2009
Conference Overview - The Empowered Patient Conference, Vancouver Island Conference Center - Including the Patient in Patient Safety
The Empowered Patient Conference
Saturday, November 7th, 2009
9:00am – 4:30pm (registration begins at 8:00am)
Vancouver Island Conference Centre, Nanaimo BC
101 Gordon Street, Nanaimo, B.C.
Would you like to play a meaningful role in your health care decisions?
Would you like to develop the knowledge and power to advocate for yourself within the health care system?
The Empowered Patient Conference is a one day event where you will develop the skills and confidence to advocate for yourself. You will hear from a range of people who are helping patients to improve safety. And you will leave empowered – knowing what to say and what to do to get the health care you deserve.
Who Should Attend?
This event was initiated by patients for patients and caregivers, including members of the public and business community, consumers of conventional and alternative health care, health care advocates, anyone living with chronic health conditions, and anyone interested in making empowered health care a reality.
Monday, October 26, 2009
U.S. NIH Research Portfolio Online Reporting Tool (RePORT) - Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC)
Note: scroll down the page for ovarian cancer
Ovarian epithelial tumors of low malignant potential: a case series of 5 adolescent patients
Ovarian epithelial tumors of low malignant potential: a case series of 5 adolescent patients
Anjali AggarwalacCorresponding Author Informationemail address, Kerith L. Luccoac, Judith Lacyac, Sari Kivesac, J. Ted Gerstlebc, Lisa Allenac
Received 7 April 2009; received in revised form 19 June 2009; accepted 23 June 2009.
Abstract
Epithelial ovarian neoplasms are uncommon in pediatric and adolescent patients, accounting for approximately 20% to 30% of ovarian tumors in adolescent females and women younger than 25. Tumors of low malignant potential (LMP) account for a significant proportion of epithelial neoplasms in this patient population. This case series describes 5 adolescent patients, with a mean age of 14.4 ± 2.4 years, diagnosed with ovarian tumors of LMP at one institution.
Between November 2001 and January 2006, 5 patients were diagnosed with ovarian tumors of LMP of 126 patients who had surgery for adnexal masses. All patients underwent initial surgery via laparotomy. Two patients underwent ovarian cystectomy, and 3 had at least a unilateral salpingo-oophorectomy. One patient had stage IIIc disease, whereas the other 4 patients, not all completely staged, had presumed stage I disease. Three patients developed recurrent ovarian masses on follow-up. Two had recurrent LMP tumors (one bilateral) and one was a benign mucinous cystadenoma.
This case series of 5 adolescent patients with ovarian tumors of LMP highlights the importance of considering epithelial neoplasms in any pediatric or adolescent patient with a pelvic mass and supports conservative management, with staging and fertility-sparing surgery; however, appropriate follow-up is essential, as evidenced by 3 of 5 patients exhibiting recurrent ovarian masses.
Sunday, October 25, 2009
Saturday, October 24, 2009
Friday, October 23, 2009
Thursday, October 22, 2009
Elevated Cancer Mortality in the Relatives of Patients with Pancreatic Cancer
Note: Pancreatic cancer is also implicated in the BRCA 2/Lynch Syndrome genetic syndromes
Wednesday, October 21, 2009
Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.
note: in 2 ovarian cancer patients (study)
Forgotten node: A case report. [World J Gastroenterol. 2009] - PubMed Result
1: World J Gastroenterol. 2009 Oct 21;15(39):4974-5.
Forgotten node: A case report.
Fratellone PM, Holowecki MA.
Fratellone Medical Associates, 47 West 57th Street 5th Floor New York, NY 10019, United States. fratmd@aol.com.
Sister Mary Joseph nodule or node refers to a palpable nodule bulging into the umbilicus and is usually a result of a malignant cancer in the pelvis or abdomen. Traditionally it has been considered a sign of ominous prognosis. Gastrointestinal malignancies, most commonly gastric, colon and pancreatic cancer account for about 52% of the underlying sources. Gynecological cancers, most commonly ovarian and uterine cancers account for about 28% of the sources.
Tuesday, October 20, 2009
Biphasic effects of hormone treatment on risk of cardiovascular disease —
"Regularly ovulating women of reproductive age are significantly protected against CVD compared with men, but CVD increases within 10 years of menopause to levels matching or exceeding incidence rates among men,13 suggesting that ovarian estrogen may help protect women against atherosclerosis. This observation led to the corollary hypothesis that treatment of postmenopausal women with estrogens (menopausal hormone therapy [MHT]) might prevent the postmenopausal increase in CVD rates. Yet, despite more than 30 years of research attempting to define whether and how postmenopausal estrogen replacement might protect women against CVD, the issue remains uncertain and, indeed, controversial...."
Monday, October 19, 2009
CBC News - Nfld. & Labrador - N.L. rate of chemo mistakes not alarming: cancer society
CBC News - Nfld. & Labrador - N.L. rate of chemo mistakes not alarming: cancer society: "A spokesperson for the Canadian Cancer Society says she isn't alarmed over revelations about the number of mistakes made during treatments in Newfoundland and Labrador."
The Director's Notes for October 16, 2009 - National Cancer Institute
"..Too often, those diagnosed with cancer hear, "The patient failed therapy," when the truth is that the therapy failed the patient.
The phrase was the subject of a 2009 commentary in The Oncologist by my colleagues Dr. Edward Benz, Jr., Director of Dana-Farber Cancer Institute in Boston, and Dr. Susan Bates from NCI's Center for Cancer Research. My hope is that in the future we will no longer need to use the word failure when it comes to treatments for cancer patients...."
Saturday, September 19, 2009
Thursday, September 17, 2009
Tuesday, September 15, 2009
Depression as a Predictor of Disease Progression and Mortality in Cancer Patients
However, it is important
to acknowledge that the overall effect sizes are relatively
small and that causality has not been absolutely
established. We would like to highlight that this meta-analysis
does not support a need for patients and their families
to feel responsible for their disease outcome if they experience
depression. It has become accepted in popular culture
that cancer patients need to maintain a positive attitude to
heroically defeat cancer, a recommendation that Spiegel and
Giese-Davis have termed an ‘‘emotional straightjacket.’’
Even if one did ascribe to this belief, the magnitude of the
effect of depression on mortality does not seem to warrant
the assignment of responsibility and blame to cancer
patients.
The Edmonton symptom assessment system--what do pa...[Support Care Cancer. 2009] - PubMed Result
The Edmonton symptom assessment system--what do pa...[Support Care Cancer. 2009] - PubMed Result: "Patients expressed a need to emphasize the timeframe as 'now'."
Monday, September 14, 2009
Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma -- Garg and Soslow 62 (8): 679 -- Journal of Clinical Pathology
Traditionally Lynch syndrome has been perceived as a CRC dominated syndrome. However, in women with Lynch syndrome, the incidence of EC equals or exceeds that of CRC2 and in more than 50% of cases, these women present with a gynaecological cancer as their first or "sentinel" malignancy.
Fabry trial set to answer "political problem" -- Silversides 181 (67): 365 -- Canadian Medical Association Journal
Fabry trial set to answer "political problem" -- Silversides 181 (67): 365 -- Canadian Medical Association Journal: "'Patients have become pawns; they are really tossed around like ping pong balls,'"
Sunday, September 13, 2009
Friday, September 11, 2009
FDA Clears a Test for Ovarian Cancer | Reuters
FDA Clears a Test for Ovarian Cancer | Reuters: "OVA1 should be used by primary care physicians or gynecologists as an adjunctive test to complement, not replace, other diagnostic and clinical procedures. OVA1 uses a blood sample to test for levels of five proteins that change due to ovarian cancer. The test combines the five separate results into a single numerical score between 0 and 10 to indicate the likelihood that the pelvic mass is benign or malignant. OVA1 is intended only for women, 18 years and older, who are already selected for surgery because of their pelvic mass. It is not intended for ovarian cancer screening or for a definitive diagnosis of ovarian cancer. Interpreting the test result requires knowledge of whether the woman is pre- or post-menopausal."
Thursday, September 10, 2009
Clinical Care Options Oncology - Ovarian Cancer—Recent Developments in the Standard of Care and Emerging Options
Clinical Care Options Oncology - Ovarian Cancer—Recent Developments in the Standard of Care and Emerging Options: "Virtual Presentations
I. Frontline Management—IP and Maintenance Therapy
II. Rising CA-125: To Treat or Not to Treat?"
Wednesday, September 09, 2009
Tuesday, September 08, 2009
Sunday, September 06, 2009
Response Letter: Anxiety and depression among long-term survivors of cancer in Australia: results of a population-based survey
Further, the authors’ assertion that psychosocial wellbeing several years after cancer diagnosis is comparable with that of the general population cannot be substantiated by studies conducted by this method.
Saturday, September 05, 2009
Time costs associated with informal caregiving for...[Cancer. 2009] - PubMed Result
Informal caregiver time costs over the 2-year period after diagnosis were the highest for caregivers of patients diagnosed with lung ..... and ovarian.
Friday, September 04, 2009
Thursday, September 03, 2009
Wednesday, September 02, 2009
Tuesday, September 01, 2009
Monday, August 31, 2009
Don't keep cancer in the family - The Irish Times - Tue, Sep 01, 2009
Don't keep cancer in the family - The Irish Times - Tue, Sep 01, 2009: "“As a society we really need to protect our patients because once you find one of these families, you have individuals with the strongest conceivable risk of cancer, far greater than smoking or any other cancer-causing agent,” he says." (Dr Henry Lynch, Sr)
Saturday, August 29, 2009
Friday, August 28, 2009
Analysis of Contemporary Trends in Access to High-Volume Ovarian Cancer Surgical Care.
in the absence of the full text, note that "high volume' may or may not include a gynecologic oncologist
Wednesday, August 26, 2009
OvPlex (UK) New blood test to detect ovarian cancer could save thousands
New blood test to detect ovarian cancer could save thousands
By Daily Mail Reporter
Last updated at 8:55 AM on 25th August 2009
A blood test that could save thousands of women's lives by detecting ovarian cancer at an early stage is to be launched in Britain.
The test, called OvPlex, is expected to be available for doctors to use by the end of the year.
It works by analysing just a few drops of blood to look for signs of five different chemicals released by tumour cells as they grow.
Tests show that when all five are detectable in the blood, there is a very good chance cancerous cells are forming on the ovaries.
Outside Australia, where the test was developed, Britain and Ireland are the first countries where it will be used to spot signs of cancer at a much earlier stage than doctors can do now.
More than 6,000 women a year in the UK are diagnosed with cancer of the ovaries and the annual death toll is around 4,500.
The disease accounts for about 5 per cent of cancer deaths in women. It is sometimes known as a 'silent killer' because, for many victims, symptoms only appear once it is already fairly advanced.
The tumours tend to grow slowly and research shows it can take an average of five years before a woman notices any symptoms and seeks medical help.
But the OvPlex test could catch cancers while they are still very small and have not spread.
If the disease is picked up early, 80 per cent of sufferers will still be alive after five years.
The main risk factors include a family history of the disease, having already had breast cancer and starting periods at a young age.
'Given the advantages of early detection of ovarian cancer, OvPlex may save many thousands of lives,' said Nick Gatsios, of HealthLinx, the Melbourne-based firm that developed it.
Dr Sarah Blagden, from the Ovarian Cancer Action Research Centre at Imperial College, London, said the OvPlex test looks 'very promising'.
Tuesday, August 25, 2009
Phase III Trial of Observation Versus Six Courses of Paclitaxel in Patients With Advanced Epithelial Ovarian Cancer in Complete Response After Six Courses of Paclitaxel/Platinum-Based Chemotherapy: Final Results of the After-6 Protocol 1 -- Pecorelli et al., 10.1200/JCO.2009.21.9691 -- Journal of Clinical Oncology
Friday, August 21, 2009
Thursday, August 20, 2009
N.E.D. | Facebook
The debut EP from N.E.D.
CD will be released to the public on 9/8/09 in both online downloadable and hard copy formats. Also, band members will be selling CDs as well.
Host:N.E.D.
Time:1:00AM Tuesday, September 8th
Location:U.S.A.
Monday, August 10, 2009
Friday, August 07, 2009
Wednesday, August 05, 2009
Cases - Losing a Comforting Ritual - Treatment - NYTimes.com
For those who have never been seriously ill, treatment often seems cut and dried. You get sick, you get treated and, in theory, you get better. One day you’re a patient, the next you’re not. Simple, right?...
Tuesday, August 04, 2009
New Gene for Ovarian Cancer - BNC2 "EYES ON DNA"
New Gene for Ovarian Cancer - BNC2: "In September 2007, I interviewed two women who’d experienced ovarian cancer – Sandi Pniauskas and Carolyn Benivegna. Sadly, Carolyn died a year later but Sandi carries on her work to bring awareness to ovarian cancer. She is urging people to sign the petition for an ovarian cancer awareness postage stamp in memory of Carolyn."
Detecting Ovarian Cancer Early: Closing In on the Holy Grail - WSJ.com
As a result, even though ovarian cancer is relatively rare—the lifetime risk is 1 in 70, compared with 1 in 8 for breast cancer—it is frequently fatal.
Monday, August 03, 2009
Print the Petition (as below)
You can cut and paste this into a word program or contact Ovacome for a better copy:
USPS Petition
Ovarian Cancer Awareness Postage Stamp
We, the undersigned, fully support the proposal initiated in 2001, and requested every year since then, by Carolyn Benivegna. This proposal requests the creation of an Ovarian Cancer Awareness Postage Stamp. The heightened awareness can help save women’s lives, and we urge you to do this as quickly as possible. We collect signatures every year. Please sign year after year for us to send to the USPS Stamp committee each year.
# Name (please print) Signature City State
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
Return signatures to and if you have questions/comments:
Ovacome - Kim Snyder 2965 164th Avenue North, Clearwater, FL 33760 Email: OvCaSurvivor@verizon.net
Online petition: http://www.ipetitions.com/petition/ovcastamp/
Sign petition for ovarian cancer please
Hello,
I am with Ovacome in Tampa, FL. I am collecting the signatures for a Ovarian Cancer USPS postage stamp project.
I have attached a signature form and the email. I would like to ask you a huge favor and see if you can have people sign the petition form.
The bottom of the page has my address. Once you have collected any signatures, please send me the signed forms.
I am collecting them to send to the USPS Stamp committee. ( Ovacome - Kim Snyder 2965 164th Avenue North, Clearwater, FL 33760 Email: OvCaSurvivor@verizon.net
Online petition: http://www.ipetitions.com/petition/ovcastamp/ ).
If you or anyone has any questions, please contact me.
Thanks,
Kim Snyder
Email: OvCaSurvivor@verizon.net
Please forward this to your friends and family.
Together we can make an OvCa stamp a reality. We have been requesting an ovarian cancer awareness postage stamp annually since 2001 and need your help. If you would like to support our goals, please sign our online petition. We will submit a request to the U.S. Postal Service along with the signatures that share in our quest to make this a reality.
In memory of Carolyn Benivegna, survivors, family and friends of those touched by ovarian cancer, please click on the link and help us send our message through the U. S. Postal Service. http://www.ipetitions.com/petition/ovcastamp
Thank you.
Kim
Ovacome
www.ovacome.org
ovcasurvivor@verizon.net
http://www.ipetitions.com/petition/ovcastamp
on behalf of the late Carolyn Benivegna: Ovarian Cancer Awareness Postage Stamp Petition : [ powered by iPetitions.com ]
Please circulate and sign this petition on behalf of not only Carolyn but ovarian cancer women and their families/friends.
Sunday, August 02, 2009
How Much Evidence Do We Need to Change Practices in Which We Firmly Believe? - Journal Watch (General)
"The chains of habit are too weak to be felt until they are too strong to be broken."
BBC NEWS | Health | Flawed gene link to ovary cancer
BBC NEWS | Health | Flawed gene link to ovary cancer: "It is the first time scientists have found a SNP linked uniquely to risk of ovarian cancer."
Saturday, August 01, 2009
Wednesday, July 29, 2009
Comparative Effectiveness Research and Evidence-Based Decision Making Across Four Countries: The U.K., Germany, France, and Australia - The Commonwealth Fund
Comparative Effectiveness Research and Evidence-Based Decision Making Across Four Countries: The U.K., Germany, France, and Australia - The Commonwealth Fund: "Comparative Effectiveness Research and Evidence-Based Decision Making Across Four Countries: The U.K., Germany, France, and Australia"
Tuesday, July 28, 2009
Microsatellite Instability and Mismatch Repair Protein Defects in Ovarian Epithelial Neoplasms in Patients 50 Years of Age and Younger
Microsatellite Instability and Mismatch Repair Protein Defects in Ovarian Epithelial Neoplasms in Patients 50 Years of Age and Younger: "This study demonstrates a 10% rate of MMR-deficient ovarian cancer in women <50 years of age. MMR-deficient ovarian cancer is frequently associated with loss of expression of MSH2 and MSH6 proteins and clear cell histology. The occurrence of MMR inactivation in a significant proportion of ovarian clear cell carcinomas (17% in this study) suggests that this tumor may warrant targeted testing in women < 50 years of age."
Monday, July 27, 2009
Ovarian Cancer Tests Flawed, in Need of New Design, Says Stanford Study
Ovarian Cancer Tests Flawed, in Need of New Design, Says Stanford Study: "Ovarian Cancer Tests Flawed, in Need of New Design, Says Stanford Study"
BioMed Central | Full text | Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.
BioMed Central | Full text | Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.: "Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study"
Sunday, July 26, 2009
Saturday, July 25, 2009
Friday, July 24, 2009
Thursday, July 23, 2009
Wednesday, July 22, 2009
European Journal of Human Genetics - Genomics and breast cancer: the different levels of inherited susceptibility
European Journal of Human Genetics - Genomics and breast cancer: the different levels of inherited susceptibility: "Other syndromes discussed in this review which may be associated with a moderately increased breast cancer risk include neurofibromatosis type 1 and Nijmegen breakage syndrome mutation carriers, and the slight increase in risk associated with Lynch syndrome is referred to, although the relative increase in breast cancer risk in Lynch syndrome is debated and generally considered to be low, but may vary with the different genes involved."
Heartfelt Tales by Physicians and Patients Inspire a Unique Online National Magazine - MarketWatch
Heartfelt Tales by Physicians and Patients Inspire a Unique Online National Magazine - MarketWatch: "Patients have written equally powerful and sometimes humorous stories about such topics as anger (when doctors miss an ovarian-cancer diagnosis)"
Tuesday, July 21, 2009
The future of cancer screening. [Prim Care. 2009] - PubMed Result
The future of cancer screening. [Prim Care. 2009] - PubMed Result: ": Prim Care. 2009 Sep;36(3):623-39.
The future of cancer screening.
Collins LG, Wynn DT, Barash JH.
Division of Geriatric Medicine, Department of Family and Community Medicine, Jefferson Medical College, Thomas Jefferson University, 1015 Walnut Street, Suite 401, Philadelphia, PA 19107, USA. Lauren.Collins@jefferson.edu
Lung and ovarian cancers are two of the most common and deadly cancers affecting men and women in the United States. The potential impact of an effective screening modality for early detection of these cancers is enormous. Yet, to date, no screening tool has been proven to reduce mortality in asymptomatic individuals, and no major organization endorses current modalities for screening for these cancers. Novel approaches, potentially relying on genomics and proteomics, may be the future for early detection of these deadly cancers."
Colorectal Cancer Risk Perception on the Basis of Genetic Test Results in Individuals at Risk for Lynch Syndrome -- Grover et al., 10.1200/JCO.2008.18.6940 -- Journal of Clinical Oncology
"Conclusion: Patients at risk for Lynch syndrome with an indeterminate genetic test result may be falsely reassured. It is important that health care providers continue to discuss the implications of uninformative results on lifetime cancer risk."
Monday, July 20, 2009
Sunday, July 19, 2009
Article Submission by Kat Sanders: CA125 and the Role of a Radiologist in Treating Cancer
CA125 and the Role of a Radiologist in Treating Cancer
http://becomingaradiologist.org/
There are various factors that cause cancer, and in the fight back against this terrible disease, mankind has discovered and invented some of the best methods of treating and managing it. One such aspect is CA125, also known as Cancer Antigen 125, a marker that can potentially detect the early stages of ovarian cancer in women. More than the diagnosis however, the role of CA125 comes to the fore in the continuing treatment and future prognosis. It helps your oncologist detect if your cancer has the potential to return or if you are well on the way to recovery.
As with any cutting edge treatment, CA125 has come it for its share of criticism when it is used as a marker to diagnose ovarian cancer. While it has been accepted as the standard in determining the future prognosis of a patient who has been diagnosed with ovarian cancer and treated for the same, there are doubts over how effective it is in helping to determine the presence of cancerous growths in the ovary. This is because women with elevated levels of CA125 in their blood are not necessarily suffering from ovarian cancer or are at risk for the disease. Also, there is no evidence to prove that the absence of or low level of CA125 is enough to rule out the possibility of ovarian cancer.
Although CA125 is primarily known for its use in treating and managing ovarian cancer, there is evidence to show that it is helpful in diagnosing other kinds of cancers like those that originate in the endometrium, breast, fallopian tubes, lungs and the gastrointestinal tract.
Recent research has found that Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is more effective than CA125 in helping to assess the recurrence of ovarian cancer and the efficacy of the treatment being followed by those who are affected by this disease.
Even so, CA125 is extremely useful in monitoring therapy for ovarian cancer and in determining the recurrence of the cancer over a period of time.
By-line:
This article is written by Kat Sanders, who regularly blogs on the topic of radiologist technician at her blog "The Overwhelmed Student" Blog. She welcomes your comments and questions at her email address: katsanders25@gmail.com.
http://becomingaradiologist.org/
Saturday, July 18, 2009
Menopausal HT and Ovarian Cancer: Causal Role Remains Unclear - Commentary on the Danish study
This is a commentary on the Danish study.
Friday, July 17, 2009
Thursday, July 16, 2009
Wednesday, July 15, 2009
Market Report -- In Play (JNJ): Trabectedin (Yondelis)
Market Report -- In Play (JNJ): Briefing.com Business News - MSN Money: "Johnson & Johnson: Centocor Ortho Biotech issues statement on the FDA ODAC opinion regarding trabectedin for relapsed ovarian cancer Co announces based on the data presented today, the FDA Oncologic Drugs Advisory Committee recommended that the combination of trabectedin when administered with DOXIL did not provide a sufficient benefit-risk profile for the treatment of relapsed ovarian cancer. Centocor Ortho Biotech Products continues to believe trabectedin has an important role in the treatment of recurrent ovarian cancer. The company remains committed to working with the FDA to address the committee's concerns. The committee provides non-binding recommendations based on its evaluation. The final decision regarding approval of the drug will be made by the FDA."
FDA panel recommends against Centocor’s trabectedin (ovarian cancer)
The Food and Drug Administration’s Oncologic Drugs Advisory Committee voted Wednesday not to recommend approval of trabectedin, an experimental cancer treatment being developed by Centocor Ortho Biotech.
Centocor Ortho Biotech of Horsham, Pa., is seeking approval of trabectedin as part of a combination therapy with the cancer drug Doxil for patients with relapsed ovarian cancer.
FDA committee recommendations are nonbinding, but the federal agency generally follows the advice of its advisory panels when making a final determination......Under a licensing agreement with PharmaMar SAU of Spain, Centocor has worldwide marketing rights for trabectedin except in Europe and Japan, where the product is marketed as Yondelis by PharmaMar.
Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas
Abstract | Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas: "Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas"
Monday, July 13, 2009
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2): "Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)"
Saturday, July 11, 2009
Friday, July 10, 2009
Thursday, July 09, 2009
Wednesday, July 08, 2009
Cancer Does Discriminate -- Couzin-Frankel 2009 (707): 1 -- ScienceNOW
Cancer Does Discriminate -- Couzin-Frankel 2009 (707): 1 -- ScienceNOW: "For advanced ovarian cancer, median survival was 1.3 years for African Americans and 2.3 years for the rest of the participants."
Southern Sask. gets a second gynecologic oncologist
The women of Saskatchewan can thank Darlene Gray and her group in large part for keeping up the pressure on this issue. OCATS is on Facebook and a new website is in progress.
Monday, July 06, 2009
Sunday, July 05, 2009
Saturday, July 04, 2009
Friday, July 03, 2009
Thursday, July 02, 2009
Cases - Losing a Comforting Ritual - Treatment - NYTimes.com
Cases - Losing a Comforting Ritual - Treatment - NYTimes.com: "For those who have never been seriously ill, treatment often seems cut and dried. You get sick, you get treated and, in theory, you get better. One day you’re a patient, the next you’re not. Simple, right?"
Tuesday, June 30, 2009
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 : Abstract : Nature Genetics
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 : Abstract : Nature Genetics: "Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2"
Saturday, June 27, 2009
Women hear advances in breast/ovarian cancer research
"Dr. Joanne Jeter said it’s important to identify and manage genetic risk factors.
She said Hispanic women face a higher risk of breast cancer than the general population; Jewish women of Ashkenazi descent, those who have ancestors from Germany, Poland, Lithuania, Ukraine and Russia, have a higher incidence of specific mutations increasing the risk of developing breast and ovarian cancer."
Center for Genomics and Public Health - EGAPP - What is EGAPP?
What is EGAPP?
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) is a project launched in 2004 by the Centers for Disease Control and Prevention (CDC) to put selected genetic tests to the test. Hundreds of genetic tests, which could give information about susceptibility to major diseases such as cancer, diabetes and heart disease, are in development. It is important for the public health community that a reliable method, based on reliable scientific evidence, be found for evaluating these tests. The EGAPP project is a key step.
EGAPP follows in the footsteps of an earlier CDC-funded project, ACCE. The ACCE project took its name from four key components of test evaluation - analytic validity, clinical validity, clinical utility, and associated ethical, legal and social implications. Evaluating five genetic tests between 2000 and 2004, ACCE served as a model for investigating the availability and quality of data on the safety and effectiveness of all DNA-based genetic tests.
Building on the knowledge gained from the ACCE project and existing U.S. recommendations for action, CDC started the EGAPP project. The intent is to both objectively assess selected tests and also to begin developing a model process for assessing all genetic tests in the future. An independent, non-federal, multidisciplinary working group is the focus of EGAPP. This working group is comprised of 13 people from the U.S. with expertise in areas such as evidence-based review, clinical practice, public health, laboratory practice, genomics, and health technology assessment.
EGAPP focuses on the process of assessing new genetic tests for their safety and usefulness. Outcomes to be considered include benefits and harms to the patient and family, as well as societal and public health issues (e.g., availability or access to testing, and adequacy of consumer and provider education).
EGAPP is commissioning evidence-based reviews of selected tests that have the potential for broad application and health impact. Genetic tests selected for review include ones that predict response to therapy, detect susceptibility for a disease in family members, or predict risk of certain diseases in healthy populations. In late 2005 EGAPP began evaluating genetic tests related to depression, colorectal cancer, and ovarian cancer. Evaluations of more tests began in the summer of 2006.
All of the evidence-based reviews conducted for EGAPP will include assessments of available information on analytic and clinical validity, and the impact of testing and subsequent interventions or treatments. Evidence reports, published summaries of evidence, and published EGAPP working group recommendations are proposed products of EGAPP.
Evidence-based reviews, which involve the systematic assessment of all of the current published, relevant medical literature, can include clinical trials and other studies of interventions. EGAPP also will consider emerging tests with limited information, as a way to identify gaps in available data.
It is expected that the EGAPP working group will include not only assessments of certain tests, but also reports on its methodological approaches to evaluating the selected tests.
Friday, June 26, 2009
Thursday, June 25, 2009
CDC's Office of Public Health Genomics Recruiting Docs for Survey on EGAPP Plans | The Sample | GenomeWeb
CDC's Office of Public Health Genomics Recruiting Docs for Survey on EGAPP Plans
June 25, 2009
* Type size: - +
* Login or register to post comments
* RSS Feed
By Kirell Lakhman
CDC's Office of Public Health Genomics today said it is recruiting "health care providers from multiple disciplines" — genetic counselors, general practitioners, oncologists, surgeons, pathologists, gastroenterologists, nurse practitioners, physicians’ assistants — "to participate in a health message survey for educational materials on the new EGAPP recommendations for Lynch Syndrome genetic testing.
The survey, to be conducted in July and August, will take about one hour to complete, OPHG says. Participants are asked to contact Sara Bedrosian.
The results should be interesting if there's any truth to what most medical societies, genetic test marketers, and individual physicians claim to be the average doc's knowledge of genetics: roughly none.
Wednesday, June 24, 2009
Cancer agency hires new doctor - news item - Darlene Gray and ovarian cancer survivours of Saskatchewan - way to go!!!
Cancer agency hires new doctor: "Currently the agency, the Ministry of Health, the Saskatoon and Regina Qu'Appelle health regions and the University of Saskatchewan college of medicine and advocacy groups are working collaboratively to put together a more comprehensive program for gynecologic oncology in Saskatchewan, Popkin said."
Technology assessment and resource allocation for predictive genetic testing: A study of the perspectives of Canadian genetic health care providers
Conclusions
Our findings suggest that largely local and relatively ad hoc decision making processes are being made in relation to resource allocations for predictive genetic tests and that a more coordinated and, potentially, national approach to allocation decisions in this context may be appropriate.
Tuesday, June 23, 2009
Sunday, June 21, 2009
Evidence and Values: Requirements for Public Reimbursement of Drugs for Rare Diseases - a Case Study in Oncology
Conclusion:
There should be a greater commitment by reimbursement agencies to a fair and transparent decisionmaking process with appropriate community input. Criteria should be developed to validate surrogate
markers for rare diseases. It should also be acknowledged that the traditional measures of benefit in
economic studies do not incorporate all elements of social value. The need should be recognized to balance equity with an efficient use of resources.
Measuring Response with FDG-PET: Methodological Aspects
Note reference to PET/CT; 1 small mention of ovarian cancer
Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial OC: GOG
"CONCLUSIONS: c-MYC amplification and polysomy 8 have limited predictive or prognostic value in suboptimally-resected, advanced stage EOC treated with platinum-based combination chemotherapy."
Saturday, June 20, 2009
Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective.
Dr Karen Lu, MDA, also noted the same risk results regarding Endometrial cancer in Lynch Syndrome women.
Avoidable waste in the production and reporting of research evidence : The Lancet
Within specific health problems there is little research on the extent to which questions addressed by researchers match questions of relevance to patients and clinicians. In an analysis of 334 studies, only nine compared researchers' priorities with those of patients or clinicians
Friday, June 19, 2009
Validation of serum biomarkers for detection of early-stage ovarian cancer
Prospective
analysis of the panel in clinical setting is
needed next to validate this panel of
biomarkers as an effective screening tool
for ovarian cancer.
A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators
This is the Rustin study which was widely debated when presented at ASCO - the one key word in the conclusion (based on the abstract) is: "alone"
Thursday, June 18, 2009
OCATS press release: June 18, 2009 Ovarian/Gyn Cancer Patient Advocates in Saskatchewan
REGINA, June 18, 2009 – Today OCATS learned that Dr. Maryam Al-Hayki, Gynecologic Oncologist for southern Sask has been contracted to provide gynecologic cancer care services for the women of Southern Saskatchewan, including chemotherapy. Many details are yet to be determined and the group of gynecologic cancer patients look forward to hearing more from the Minister of Health Don McMorris. The Ministry, SaskHealth, Sask Cancer Agency and the Health Regions all working towards the implementation of a proper Gynecologic Oncology Program for Saskatchewan, with a Unit each in Regina and Saskatoon, and now with this contract; we hope that all four of Saskatchewan’s gynecologic cancer specialists will be retained for a long time to come. With this progress it is also hopeful that additional gynecologic oncologists can be recruited.
A long time request of the OCATS group to meet with the Minister of Health, Don McMorris has now been scheduled for Monday, June 29th at 11:00 a.m. A Director of OCATS, Darlene Gray said, “we are so relieved to hear that a contract has been extended to Dr. Al-Hayki and we hope it is a contract that will keep her here for a long time. Hopefully, this will result in immediate oncologist availability for patients of all cancers. Patients also need to be assured that a proper gyne oncology program is established to ensure the retention of both Dr. Al-Hayki and Dr. Brydon in Regina and the two specialists in Saskatoon. We are pleased but still have many questions.”
The OCATS group expects to hear more at a meeting with all the stakeholders including SaskHealth, Sask Cancer Agency, the health regions and the women’s cancer specialists this coming week as soon as all the participants can meet. Ms. Gray said, “We are very much appreciative of this opportunity to hear about the program in full and also to provide our input, since all we have right now is a theory. Women need to know that all the resources and funding will be in place to ensure the gynecologic oncology Units in Regina and Saskatoon will have all specialists, support staff, technical and diagnostic testing and tools are in place. We hope to see a plan for trained or a training program for technicians to run the new ultrasounds, pathology and educational instruments and programs required for a true gynecologic oncology program.”
Darlene was clear in stating that, “This has been a stressful time for the volunteers in our group and a very worrisome time for patients needing chemotherapy and other treatment, as it has been for the doctors and administrators. We are relieved, happy and a bit shell shocked. It’s comforting, for all I’m sure, to know that the specialists can go back to the business of treating patients. We want to thank the Ministry and all the bureaucracies involved for doing the right thing for women in Saskatchewan, current and future patients. We feel that once the administrators understood how urgent and critical the gynecologic cancer situation in Saskatchewan was, everyone moved very quickly to put a solution together. We hope to make our gratitude known at these upcoming meetings. Still, we feel that a patient’s experience must be included in the process and we look forward to providing that to the Minister of Health personally on June 29th, and to the team in the upcoming week. This is a wonderful beginning.”
For more information contact Darlene Gray in Regina at 306-775-1848, cell 529-3199 or in Fort San at 306-332-3957, or darlenegray@sasktel.net
Wednesday, June 17, 2009
Hormone Replacement Therapy: Real Concerns and False Alarms : The Cancer Journal
Hormone Replacement Therapy: Real Concerns and False Alarms : The Cancer Journal: "Hormone Replacement Therapy: Real Concerns and False Alarms"
Tuesday, June 16, 2009
Effect of Surgeon Training, Specialization and Experience on Outcomes for Cancer Surgery-a Systematic Review of the Literature
"RESULTS:
The 29 articles that met the inclusion criteria examined
nine different types of cancers including colorectal, ovarian,
melanoma, breast, bladder, lung, esophageal, gastric,
and hepatocellular.12–36 Fifteen different physician specialties
were assessed, including colorectal surgery,
transplant surgery, vascular surgery, dermatology, general
practitioners, plastic surgery, surgical oncology, hepatopancreaticobiliary,
urology, urologic oncology, thoracic
surgery, cardiothoracic surgery, obstetrics and gynecology,
gynecologic oncology, and general surgery. Four articles
examined outcomes based on the surgeon’s years of
experience. The main outcome measures assessed were
perioperative morbidity, mortality, recurrence, and longterm
survival. Characteristics and results of each study are
summarized in Table 1."
AJCC Cancer Staging Manual/Handbook Nov 2009 ($$)
"The AJCC Cancer Staging Manual and Handbook, prepared by the American Joint Committee on Cancer, are used throughout the world to facilitate the uniform description of neoplastic diseases.
The fully revised and updated 7th Edition is uniform between the AJCC and UICC and brings together all currently available information on staging of cancer at various anatomic sites and incorporates newly acquired knowledge on the etiology and pathology of cancer."
AJCC Cancer Staging Manual
http://www.springer.com/medicine/surgery/book/978-0-387-88440-0?cm_mmc=AD-_-Enews-_-CLM11050_V1-_-0
AJCC Cancer Staging Handbook
http://www.springer.com/medicine/surgery/book/978-0-387-88442-4?cm_mmc=AD-_-Enews-_-CLM11050_V1-_-0
Monday, June 15, 2009
Cancer Genome Sequencing--An Interim Analysis
Most significantly, however, the cancer genome sequencing strategy, as currently applied, fails to characterize the most relevant genomic features of cancer—the mutational heterogeneity within individual tumors.
Saturday, June 13, 2009
Friday, June 12, 2009
Thursday, June 11, 2009
Lung Cancer Risks Rise With Nanoparticles, Lung Cancer
Editorial comment (mine):
I had written concerning this issue before, but new info/repeat for newer members. Some years ago, I had spoken with a well known researcher while discussing family histories of ovarian cancer because in a small non-scientific study we had done, it seemed certain cancers were very prevelant and outside of what might be considered the norm. Lung cancer was one. The researcher at the time said that they believed there is was/is a genetic component between ovarian and lung cancer, aside from both being epithelial (the lining of an organ) cancers. It seems, although not specific, this article is starting to document these concerns/advances. Anyway, a FYI, but mostly it is because over years I have witnessed lung cancer patients being ostracized not only by the public by others. I hope some now take a reflective look when judging those most in need. Anyway, a bit off topic but I think it important not only for cancer communities but for all.
....................................................................................
http://www.emaxhealth.com/1075/99/31666/lung-cancer-risks-rise-nanoparticles.html
> More recent studies point to the cause of lung cancer as possibly genetic. While researchers insist environmental factors, such as smoking, asbestos exposure, etc., play a role in the development of the disease, there is growing evidence that the answer to the question is at the gene level.
Lung Cancer Risks Rise With Nanoparticles, Lung Cancer: "More recent studies point to the cause of lung cancer as possibly genetic. While researchers insist environmental factors, such as smoking, asbestos exposure, etc., play a role in the development of the disease, there is growing evidence that the answer to the question is at the gene level."
abstract: Palliative care in gyn oncology
Article Outline
Introduction
Pain relief
Nausea and vomiting
Constipation
Bowel obstruction
Recurrent ascites
Genital fistulas
Bleeding
Psychosocial issues
Conclusion
Further Reading
Sanofi-aventis Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites
"The results of this Phase 2, placebo-controlled study demonstrate that aflibercept is a clinically active agent in patients with advanced ovarian cancer with symptomatic malignant ascites. However, given the small number of patients enrolled in this study and the fragile health status of these advanced ovarian cancer patients, who had a median survival of only about three to four months, it is difficult to definitively assess the overall clinical benefit that might be derived from treatment in the real-world clinical practice setting," stated George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories. "Therefore, we and sanofi-aventis have decided not to submit these Phase 2 data for accelerated approval in symptomatic malignant ascites.
We will focus our efforts on completing the current Phase 3 program which combines aflibercept with standard chemotherapy regimens for the treatment of earlier stage metastatic colorectal, non-small cell lung, pancreatic, and prostate cancers, which should begin delivering data in 2010."
Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial.
Title: Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial.
Author: Timmers PJ; Zwinderman AH; Teodorovic I; Vergote I; Trimbos JB
Journal: Int J Gynecol Cancer; 2009 Jan; 19(1):88-93. PubMed ID: 19258948
Abstract:
BACKGROUND: An analysis was performed comparing survival of patients with clear cell carcinoma (CCC) to patients with serous adenocarcinoma (SAC) in early ovarian cancer. Furthermore, a literature search was done to clarify the clinical and histopathological features of clear cell tumors of the ovary. METHODS: Between November 1990 and March 2000, 448 patients with ovarian cancer International Federation of Gynecology and Obstetrics stages I to IIa were enrolled in the European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm Trial, a randomized study comparing adjuvant platinum-based chemotherapy to observation after surgical treatment in patients with early ovarian cancer. RESULTS: Sixty-three patients (14.1%) with CCC were compared with 156 patients (34.8%) with serous tumors. A significant difference was found in the International Federation of Gynecology and Obstetrics stage Ic with capsule rupture, 28 (44.4%) of 63 patients with CCC and 29 (18.6%) of 156 patients with SAC
Found: One in Three Billion : BC Cancer Agency The spelling mistake in the genetic code that causes a type of Ovarian Cancer
06/10: Found: One in Three Billion : BC Cancer Agency: "The spelling mistake in the genetic code that causes a type of Ovarian Cancer"
Wednesday, June 10, 2009
Tuesday, June 09, 2009
Raitt wanted credit for fixing 'sexy' isotope crisis: tape
Raitt wanted credit for fixing 'sexy' isotope crisis: tape: "sandipn, 09:09 AM EDT � Tuesday, June 9th, 2009
"What I think cannot be published. Cancer Survivor"
the key point: Making trials matter: pragmatic and explanatory trials and the problem of applicability
"....Readers need to know ‘who, what, when and where’...."
Monday, June 08, 2009
Sunday, June 07, 2009
Saturday, June 06, 2009
Friday, June 05, 2009
The Director's Notes for June 4, 2009 - National Cancer Institute
The Director's Notes for June 4, 2009 - National Cancer Institute: "Last Monday, I met with a new coalition of advocacy organizations concerned with a group of cancers - brain, esophagus, liver, lung, myeloma, pancreas, ovarian, and stomach - each with a survival rate of less than 50 percent. Representing 20 different organizations, the group presented data showing that 276,040 deaths (49.1 percent of the cancer deaths predicted in 2009) will come from those eight forms of cancer. The advocates are concerned that those same cancers only account for approximately 18 percent of the NCI funded research portfolio, and they seek a greater emphasis on these cancers........."
Thursday, June 04, 2009
Facebook | Ovarian Cancer Awareness & Treament in Saskatchewan (OCATS)
Facebook | Ovarian Cancer Awareness & Treament in Saskatchewan (OCATS)
June 2nd, 2009
OCATS has just become OCATS Inc., a non-profit organization in Sask. We are just this week applying for status as a charitable organization with the federal government. You could really help us out by becoming a formal member, this requires only a $10 fee and the complete an application which I can only send you by email or snail mail. Please consider helping us this way - not only would it help with our expenses but would also help us widen our base so we can raise awareness with a greater number of people. Thank you for your consideration.
Darlene, darlenegray@sasktel.net
Prospective study of physical activity and the risk of ovarian cancer
Conclusions Neither moderate nor vigorous physical activity showed a statistically significant association with ovarian cancer in this large cohort of women.
Clinical Care Options Oncology - 2009 American Society of Clinical Oncology Annual Meeting audio - re: CA125 Dr Thigpen
J. Tate Thigpen, MD, discusses important findings in ovarian cancer, including findings from the CALYPSO trial, outcomes of a study evaluating delayed or early treatment of patients with rising CA-125, and findings from a phase III trial of gemcitabine plus cisplatin and radiation in cervical cancer patients. (7 minutes)
Wednesday, June 03, 2009
NEJM -- A Strategy for Health Care Reform -- Toward a Value-Based System
NEJM -- A Strategy for Health Care Reform -- Toward a Value-Based System: "strategy centered on value. This undertaking is complex, but the only real solution is to align everyone in the system around a common goal: doing what's right for patients."
Dr Maurie Markman's comments: re: CA125/survival ASCO....
Cancerwise | A blog featuring Cancer News and Insights from M. D. Anderson
Surveillance of CA-125 in Women With Advanced Ovarian Cancer
By Cancerwise Blogger on June 2, 2009 9:34 AM
By Maurie Markman, M.D., Vice President for Clinical Research, from ASCO 2009
The abstract from Rustin, et al, dealing with the clinical utility of routine surveillance of CA-125 in women with advanced ovarian cancer who attain a complete clinical remission following cytotoxic chemotherapy has the potential to change the standard management paradigm in this clinical setting.
This well-designed and conducted Phase III randomized trial revealed that patients who initiated treatment for recurrent disease solely based on an elevated CA-125 antigen (in the complete absence of any signs or symptoms of cancer) did not experience superior survival compared to women who experienced recurrence but whose therapy was started due to other manifestations of the malignancy (for example, a return of abdominal symptoms).
However, it is critically important to recognize what this study does not state.
First, there is no statement that patients treated in this trial failed to experience benefit from the treatment of recurrence, but only that it was possible to delay reintroduction of treatment until symptoms developed.
Second, there is no statement that CA-125 should be avoided in a patient who experiences symptoms. In fact, in this setting, a serum CA-125 level can be particularly helpful since symptoms of recurrent ovarian cancer can be quite non-specific. In a woman who has previously undergone a major abdominal surgical procedure, interference with bowel function (often due to adhesions) can appear to be due to progressive cancer when in reality the discomfort is secondary to the effects of the previous surgery.
The finding of a normal CA-125 antigen level in this situation can be helpful, while an elevated value would likely lead to future investigation (e.g., abdominal/pelvic CT scan) and possible re-introduction of anti-neoplastic treatment.
Adaptive Therapy -- reference to Carboplatin
Major Findings:
We present mathematical analysis of the evolutionary dynamics of tumor populations with and without therapy. Analytic solutions and numerical simulations show that, with pretreatment, therapy-resistant cancer subpopulations are present due to phenotypic or microenvironmental factors; maximum dose density chemotherapy hastens rapid expansion of resistant populations. The models predict that host survival can be maximized if "treatment-for-cure strategy" is replaced by "treatment-for-stability." Specifically, the models predict that an optimal treatment strategy will modulate therapy to maintain a stable population of chemosensitive cells that can, in turn, suppress the growth of resistant populations under normal tumor conditions (i.e., when therapy-induced toxicity is absent). In vivo experiments using OVCAR xenografts treated with carboplatin show that adaptive therapy is feasible and, in this system, can produce long-term survival.
Tuesday, June 02, 2009
Monday, June 01, 2009
Subscribe to:
Posts
(
Atom
)
